From the Advanced Heart Failure and Transplantation Center, Department of Cardiology, UMC Ljubljana, Slovenia (B.V.).
Division of Cardiovascular Medicine, Institute of Molecular Cardiology, University of Louisville, KY (R.B.).
Circ Res. 2019 Mar;124(5):690-692. doi: 10.1161/CIRCRESAHA.118.314653.
Despite encouraging preclinical findings, clinical trials of repeated cell therapy are relatively scarce. As a result, the potential of this treatment paradigm remains to be assessed. We propose that a carefully planned clinical trial design using repeated cell dosing could lead to significant progress in the field of cell therapy.
尽管临床前研究结果令人鼓舞，但重复细胞治疗的临床试验相对较少。因此，这种治疗模式的潜力仍有待评估。我们建议使用重复细胞剂量的精心设计的临床试验设计可以推动细胞治疗领域的重大进展。
